Organisation paid for research Program year 2025 Source: CMS Open Payments

Retinal Research Institute LLC

Neither a doctor nor a teaching hospital

Research payments

$2,597,494

591 payments

Through program year 2025, Retinal Research Institute LLC is reported as receiving $2,597,494 in research payments, across 591 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $406,923 244
2024 Research $169,267 80
2023 Research $435,252 60
2022 Research $310,211 62
2021 Research $308,673 59
2020 Research $655,136 45
2019 Research $312,032 41

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $1,268,833 180 payments
  2. Novartis Pharmaceuticals Corporation $484,286 12 payments
  3. Ocular Therapeutix, Inc. $194,209 39 payments
  4. Roche TCRC, Inc. $159,498 15 payments
  5. Apellis Pharmaceuticals, Inc. $141,250 49 payments
  6. F. Hoffmann-La Roche AG $83,915 123 payments
  7. Aerie Pharmaceuticals, Inc. $74,733 21 payments
  8. Regeneron Pharmaceuticals, Inc. $45,923 104 payments
  9. Allergan Inc. $42,727 21 payments
  10. EyePoint Pharmaceuticals US, Inc. $38,010 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. Va2 Phiii Rhine $349,052 24 payments
  2. A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $302,890 2 payments
  3. Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration $194,209 39 payments
  4. A Multicenter Randomized Double Masked Phase 3A Study to Assess Safety and Efficacy of Brolucizumab 6 MG Q4 Weeks Compared to Aflibercept 2 MG Q4 Weeks in Patients With Neovascular Age Related MacUlar Degeneration Namd With Persistent Retinal Fluid $176,071 5 payments
  5. A Phase III Study to Evaluate Faricimab in Patients With Central Retinal Vein Occlusion $163,595 10 payments
  6. A Phase 1 Sad MD in Diabetic MacUlar Edema $153,308 21 payments
  7. Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $137,796 42 payments
  8. Port Delivery System of Ranibizumab Extension Study $103,650 26 payments
  9. Entry Into Human of Ro7497372 in Participants With Diabetic MacUlar Edema $85,465 6 payments
  10. Real World Long Term Data Collection for Roche Ophthalmology Products Voyager $83,915 123 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record